Add Company
Join Now

Ionetix Corporation Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Ionetix Corporation's estimated annual revenue is currently $14.9M per year.(i)
  • Ionetix Corporation's estimated revenue per employee is $201,000

Employee Data

  • Ionetix Corporation has 74 Employees.(i)
  • Ionetix Corporation grew their employee count by 17% last year.

Ionetix Corporation's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
COOReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, Clinical Affairs and Mobile OperationsReveal Email/Phone
5
VP Facilities and Construction MgmtReveal Email/Phone
6
VP Medical AffairsReveal Email/Phone
7
Vice Pesident Research and DevelopmentReveal Email/Phone
8
VP Sales & MarketingReveal Email/Phone
9
VP, Site OperationsReveal Email/Phone
10
VP Regulatory Affairs & Quality AssuranceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Ionetix Corporation?

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. We are changing the paradigm when it comes to access to one of the most accurate PET imaging agents for the detection of coronary artery disease, N-13 Ammonia. Until now, this tracer was only available to a select group of institutions due to its very short half-life and the need for a large and expensive cyclotron on site. Ionetix can now provide virtually any hospital or private center with on demand N-13 Ammonia doses without the need to purchase a cyclotron!

keywords:N/A

N/A

Total Funding

74

Number of Employees

$14.9M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18M741%N/A
#2
$7.5M741%N/A
#3
$9M74-26%$235.7M
#4
$7.5M74-5%N/A
#5
$11M74N/AN/A